Skip to main content

Table 2 CEA of peginterferon beta-1a vs IFN beta-1b and GA in Italy from the NHS perspective

From: The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy

Outcomes

 

peginterferon beta-1a 125 μg

IFN beta-1b 250 μga

IFN beta-1a 250 μgb

GA 20 mg

Clinical outs.

LYs

19.94

19.68

19.68

19.68

 

QALYs

9.07

8.06

8.06

8.15

[a]

  

1.01

1.01

0.92

Cost outs. (€)

Drugs & mon.

113,095

92,105

86,019

82,887

 

Relapses

8789

8808

8808

8502

 

Adverse events

102

110

110

94

 

Disease manag.

111,107

121,277

121,277

121,424

 

Total cost

233,091

222,399

216,213

212,908

[b]

  

10,691

16,877

20,183

ICER (€) [c]

  

10,580

16,702

22,023

  1. outs. = outcomes
  2. drugs & mon. = treatment acquisition and monitoring
  3. manag. = management
  4. [a] = Incremental benefit (QALYs) (peginterferon beta-1a vs comparators)
  5. [b] = Incremental cost (total) (peginterferon beta-1a vs comparators)
  6. [c] = [b]/[a]
  7. aBetaferon
  8. bExtavia